logo
Plus   Neg
Share
Email

Lipocine Enrolling Patients Into Open Label Extension To LPCN 1144 Phase 2 LiFT Study

Lipocine Inc. (LPCN), a clinical-stage biopharmaceutical company, said Wednesday it is enrolling patients into an open label extension to the ongoing LPCN 1144 Phase 2 LiFT study, based on investigator and patient interest in continuing treatment.

The LiFT (Liver Fat intervention with oral Testosterone) clinical study is a paired-biopsy study that is investigating LPCN 1144 in confirmed non-cirrhotic non-alcoholic steatohepatitis or NASH subjects.

Lipocine noted that in the initial, double-blind part of the LiFT study, patients were randomized to receive one of two treatments of LPCN 1144 or placebo over 36 weeks.

Patients who complete this portion can now opt to enter the 36-week open label extension study, which is designed to evaluate the long-term safety and tolerability of LPCN 1144 treatment. There is no placebo arm in the open label extension study, and all patients will be treated with LPCN 1144.

"This extension to our ongoing LiFT clinical study will allow us to collect additional data on LPCN 1144 for up to a total of 72 weeks of therapy. Patients who may have received placebo during the initial, randomized part of the trial now have the opportunity to receive active drug," said Dr. Mahesh Patel, Chairman, President and Chief Executive Officer of Lipocine.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration is hastening its efforts to make available more at-home testing options in response to the ongoing COVID-19 pandemic. All At-Home Covid-19 Tests being used now are authorized only for emergency use, and not cleared or fully approved by the FDA. The recent granting of EUA for the Quidel Corp.'s QuickVue At-Home COVID-19 Test is one example. Dollar Tree Inc. (DLTR) Wednesday reported a profit for the fourth-quarter that climbed 309 percent from last year, while Wendy's Co. (WEN) posted a profit that grew about 46.0 percent from the prior year. Dollar Tree has increased its share repurchase authorization by $2.0 billion. Wendy's expects profit for fiscal year 2021 to be below analysts' expectations. Medical devices company Boston Scientific Corp. (BSX) agreed Wednesday to acquire the global surgical business of Israel-based Lumenis LTD from an affiliate of Baring Private Equity Asia (BPEA) for an upfront cash payment of $1.07 billion, subject to closing adjustments. Lumenis is a privately-held...
Follow RTT